- Home
- GPRK vs CELC Comparison
GPRK vs CELC Comparison
Compare GPRK & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRK
- CELC
- Stock Information
- Founded
- GPRK 2002
- CELC 2011
- Country
- GPRK Colombia
- CELC United States
- Employees
- GPRK N/A
- CELC N/A
- Industry
- GPRK Oil & Gas Production
- CELC Medical Specialities
- Sector
- GPRK Energy
- CELC Health Care
- Exchange
- GPRK Nasdaq
- CELC Nasdaq
- Market Cap
- GPRK 396.7M
- CELC 391.0M
- IPO Year
- GPRK N/A
- CELC 2017
- Fundamental
- Price
- GPRK $8.07
- CELC $9.29
- Analyst Decision
- GPRK Strong Buy
- CELC Strong Buy
- Analyst Count
- GPRK 2
- CELC 6
- Target Price
- GPRK $12.50
- CELC $30.17
- AVG Volume (30 Days)
- GPRK 768.3K
- CELC 260.9K
- Earning Date
- GPRK 03-05-2025
- CELC 05-14-2025
- Dividend Yield
- GPRK 7.29%
- CELC N/A
- EPS Growth
- GPRK N/A
- CELC N/A
- EPS
- GPRK 1.84
- CELC N/A
- Revenue
- GPRK $660,800,000.00
- CELC N/A
- Revenue This Year
- GPRK $6.79
- CELC N/A
- Revenue Next Year
- GPRK $1.54
- CELC N/A
- P/E Ratio
- GPRK $4.40
- CELC N/A
- Revenue Growth
- GPRK N/A
- CELC N/A
- 52 Week Low
- GPRK $7.24
- CELC $8.50
- 52 Week High
- GPRK $11.72
- CELC $20.89
- Technical
- Relative Strength Index (RSI)
- GPRK 47.51
- CELC 35.82
- Support Level
- GPRK $7.66
- CELC $9.98
- Resistance Level
- GPRK $8.33
- CELC $10.91
- Average True Range (ATR)
- GPRK 0.29
- CELC 0.74
- MACD
- GPRK 0.07
- CELC -0.01
- Stochastic Oscillator
- GPRK 55.42
- CELC 29.59
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil and Argentina. The company generates revenue from the sale of crude oil, condensate and natural gas net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.